iTRAQ-based quantitative proteomic analysis of differentially expressed proteins in chemoresistant nasopharyngeal carcinoma

References

• Dükel M, Streitfeld WS, Tang TC, Backman LR, Ai L, May WS, Brown KD. The breast cancer tumor suppressor TRIM29 is expressed via ATM-dependent signaling in response to hypoxia. J Biol Chem. 2016;291(41):21541–21552. PMID: 27535224. doi:10.1074/jbc.M116.730960.
   PubMed Web of Science ®Google Scholar
• Xu J, Li Z, Su Q, Zhao J, Ma J. TRIM29 promotes progression of thyroid carcinoma via activating P13K/AKT signaling pathway. Oncol Rep. 2017;37(3):1555–1564. PMID:28098872. doi:10.3892/or.2017.5364.
   PubMed Web of Science ®Google Scholar
• Xu R, Hu J, Zhang T, Jiang C, Wang HY. TRIM29 overexpression is associated with poor prognosis and promotes tumor progression by activating Wnt/β-catenin pathway in cervical cancer. Oncotarget. 2016;7:28579–28591. PMID:27081037. doi:10.18632/oncotarget.8686.
   PubMedGoogle Scholar
• Zhou XM, Sun R, Luo DH, Sun J, Zhang MY, Wang MH, Yang Y, Wang HY, Mai SJ. Upregulated TRIM29 promotes proliferation and metastasis of nasopharyngeal carcinoma via PTEN/AKT/mTOR signal pathway. Oncotarget. 2016;7(12):13634–13650. doi:10.18632/oncotarget.7215.PMID:26872369.
   PubMedGoogle Scholar
• Twu CW, Wang WY, Chen CC, Liang KL, Jiang RS, Wu CT, Shih YT, Lin PJ, Liu YC, Lin JC. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma epstein-barr virus deoxyribonucleic acid. Int J Radiat Oncol Biol Phys. 2014;89(1):21–29. PMID: 24725686. doi:10.1016/j.ijrobp.2014.01.052.
   PubMed Web of Science ®Google Scholar
• Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, Li NW, Xiang YQ, Luo DH, Qiu F, et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst. 2011;103(23):1761–1770. PMID: 22056739. doi:10.1093/jnci/djr432.
   PubMed Web of Science ®Google Scholar
• OuYang PY, Xie C, Mao YP, Zhang Y, Liang XX, Su Z, Liu Q, Xie FY. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. Ann Oncol. 2013;24(8):2136–2146. PMID: 23613477. doi:10.1093/annonc/mdt146.
   PubMed Web of Science ®Google Scholar
• Peng X, Li W, Tan G. Reversal of taxol resistance by cisplatin in nasopharyngeal carcinoma by upregulating thromspondin-1 expression. Anticancer Drugs. 2010;21(4):381–388. PMID: 20051827. doi:10.1097/CAD.0b013e3283363980.
   PubMed Web of Science ®Google Scholar
• Ma BB, Hui EP, Wong SC, Tung SY, Yuen KK, King A, Chan SL, Leung SF, Kam MK, Yu BK, et al. Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma–correlation with excision repair cross-complementing-1 polymorphisms. Ann Oncol. 2009;20(11):1854–1859. PMID: 19549713. doi:10.1093/annonc/mdp065.
   PubMed Web of Science ®Google Scholar
• Zuo Q, Shi M, Li L, Chen J, Luo R. Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance. Biomed Pharmacother. 2010;64(8):550–558. PMID: 20630698. doi:10.1016/j.biopha.2010.03.003.
   PubMed Web of Science ®Google Scholar
• Xie SM, Fang WY, Liu TF, Yao KT, Zhong XY. Association of ABCC2 and CDDP-resistance in two sublines resistant to CDDP derived from a human nasopharyngeal carcinoma cell line. J Oncol. 2010;2010:915046. PMID: 20628484. doi:10.1155/2010/915046.
   PubMedGoogle Scholar
• Bao YN, Cao X, Luo DH, Sun R, Peng LX, Wang L, Yan YP, Zheng LS, Xie P, Cao Y, et al. Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis. Cell Cycle. 2014;13(12):1958–1969. PMID: 24763226. doi:10.4161/cc.28921.
   PubMed Web of Science ®Google Scholar
• Cai YL, Li J, Lu AY, Zheng YM, Zhong WM, Wang W, Gao JQ, Zeng H, Cheng JR, Tang MZ. Diagnostic significance of combined detection of epstein-barr virus antibodies, VCA/ IgA,EA/IgA, Rta/IgG and EBNA1/IgA for nasopharyngeal carcinoma. Asian Pac J Cancer Prev. 2014;15(5):2001–2006. PMID:24716925. doi:10.7314/APJCP.
   PubMedGoogle Scholar
• Huang D, Li Y, Liu N, Zhang Z, Peng Z, Duan C, Tang X, Tan G, Yan G, Tang F. Identification of novel signaling components in N,N’-dinitrosopiperazine-mediated metastasis of nasopharyngeal carcinoma by quantitative phosphoproteomics. BMC Cancer. 2014;14(1):243. PMID: 24708550. doi:10.1186/1471-2407-14-243.
   PubMedGoogle Scholar
• Zheng PC, Chen X, Zhu HW, Zheng W, Mao LH, Lin C, Liu JN, Zheng M. 2014. Capn4 is a marker of poor clinical outcomes and promotes nasopharyngeal carcinoma metastasis via NF-kappaB-Induced MMP2 expression. Cancer Sci. 105(6):630–638. PMID: 24703594. doi:10.1111/cas.12416.
   PubMed Web of Science ®Google Scholar
• Wang W, Jia HL, Huang JM, Liang YC, Tan H, Geng HZ, Guo LY, Yao SZ. Identification of biomarkers for lymph node metastasis in early-stage cervical cancer by tissue-based proteomics. Br J Cancer. 2014;110(7):1748–1758. PMID: 24569473. doi:10.1038/bjc.2014.92.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Suarez E, Mato JM, Elortza F. Proteomics analysis of human nonalcoholic fatty liver. Methods Mol Biol. 2012;909:241–258. PMID: 22903720. doi:10.1007/978-1-61779-959-4_16.
   PubMedGoogle Scholar
• Mustafa MG, Petersen JR, Ju H, Cicalese L, Snyder N, Haidacher SJ, Denner L, Elferink C. Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C-infected patients. Mol Cell Proteomics. 2013;12(12):3640–3652. PMID: 24008390. doi:10.1074/mcp.M113.031252.
   PubMed Web of Science ®Google Scholar
• Barjaktarovic Z, Anastasov N, Azimzadeh O, Sriharshan A, Sarioglu H, Ueffing M, Tammio H, Hakanen A, Leszczynski D, Atkinson MJ, et al. Integrative proteomic and microRNA analysis of primary human coronary artery endothelial cells exposed to low-dose gamma radiation. Radiat Environ Biophys. 2013;52(1):87–98. PMID: 23138885. doi:10.1007/s00411-012-0439-4.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li Y, Tan BB, Zhao Q, Fan LQ, Zhang ZD, Li ZX. Technique appraisement of comparative proteomics and screening of differentiation-related protein in gastric carcinoma. Hepatol gastroentero. 2013;60(123):633–637. PMID: 23635446. PMID: 24769235. doi:10.5754/hge12794.
   Google Scholar
• Liu Y, Wang X, Li S, Hu H, Zhang D, Hu P, Yang Y, Ren H. The role of von willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: a quantitative proteomic based study. J Proteomics. 2014;106:99–112. PMID: 24769235. doi:10.1016/j.jprot.2014.04.021.
   PubMed Web of Science ®Google Scholar
• Datta A, Chen CP, Sze SK. Discovery of prognostic biomarker candidates of lacunar infarction by quantitative proteomics of microvesicles enriched plasma. PLoS One. 2014;9(4):e94663. PMID: 24752076. doi:10.1371/journal.pone.0094663.
   PubMed Web of Science ®Google Scholar
• Serada S, Naka T. Screening for novel serum biomarker for monitoring disease activity in rheumatoid arthritis using iTRAQ technology-based quantitative proteomic approach. Methods Mol Biol. 2014;1142:99–110. PMID: 24706280. doi:10.1007/978-1-4939-0404-4_12.
   PubMedGoogle Scholar
• Zeng GQ, Zhang PF, Deng X, Yu FL, Li C, Xu Y, Yi H, Li MY, Hu R, Zuo JH, et al. Identification of candidate biomarkers for early detection of human lung squamous cell cancer by quantitative proteomics. Mol Cell Proteomics. 2012;11(6):M111.013946. M111.013946.PMID:22298307. doi:10.1074/mcp.
   Web of Science ®Google Scholar
• Sahasrabuddhe NA, Barbhuiya MA, Bhunia S, Subbannayya T, Gowda H, Advani J, Shrivastav BR, Navani S, Leal P, Roa JC, et al. Identification of prosaposin and transgelin as potential biomarkers for gallbladder cancer using quantitative proteomics. Biochem Biophys Res Commun. 2014;446(4):863–869. PMID: 24657443. doi:10.1016/j.bbrc.2014.03.017.
   PubMed Web of Science ®Google Scholar
• Singh AK, Roberts S, Ullman B, Madhubala R. A quantitative proteomic screen to identify potential drug resistance mechanism in alpha-difluoromethylornithine (DFMO) resistant leishmania donovani. J Proteomics. 2014;102:44–59. PMID: 24631822. doi:10.1016/j.jprot.2014.02.030.
   PubMed Web of Science ®Google Scholar
• White NM, Masui O, Desouza LV, Krakovska O, Metias S, Romaschin AD, Honey RJ, Stewart R, Pace K, Lee J, et al. Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma. Oncotarget. 2014;5(2):506–518. PMID: 24504108. doi:10.18632/oncotarget.1529.
   PubMed Web of Science ®Google Scholar
• Datta A, Qian J, Chong R, Kalaria RN, Francis P, Lai MK, Chen CP, Sze SK. Novel pathophysiological markers are revealed by iTRAQ-based quantitative clinical proteomics approach in vascular dementia. J Proteomics. 2014;99:54–67. PMID: 24448401. doi:10.1016/j.jprot.2014.01.011.
   PubMed Web of Science ®Google Scholar
• Jamshed A, Hussain R, Iqbal H. Gemcitabine and cisplatin followed by chemo-radiation for advanced nasopharyngeal carcinoma. Asian Pac J Cancer Prev. 2014;15(2):899–904. PMID: 24568516. doi:10.7314/APJCP.2014.15.2.899.
   PubMedGoogle Scholar
• Zhang P, Liu H, Xia F, Zhang QW, Zhang YY, Zhao Q, Chao ZH, Jiang ZW, Jiang CC. Epithelial-mesenchymal transition is necessary for acquired resistance to cisplatin and increases the metastatic potential of nasopharyngeal carcinoma cells. Int J Mol Med. 2014;33(1):151–159. PMID: 24173500. doi:10.3892/ijmm.2013.1538.
   PubMed Web of Science ®Google Scholar
• Liu X, Chen L, Feng B, Liu G. Reversing effect of sorcin in the drug resistance of human nasopharyngeal carcinoma. Anat Rec (Hoboken). 2014;297(2):215–221. PMID: 24376145. doi:10.1002/ar.22832.
   PubMedGoogle Scholar
• Tang S, Huang W, Zhong M, Yin L, Jiang H, Hou S, Gan P, Yuan Y. Identification keratin 1 as a cDDP-resistant protein in nasopharyngeal carcinoma cell lines. J Proteomics. 2012;75(8):2352–2360. PMID: 24376145. doi:10.1002/ar.22832.
   PubMed Web of Science ®Google Scholar
• Pan Y, Zhang Q, Atsaves V, Yang H, Claret FX. Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways. Oncogene. 2013;32(22):2756–2766. PMID: 22797071. doi:10.1038/onc.2012.294.
   PubMed Web of Science ®Google Scholar
• Pan Y, Zhou F, Zhang R, Claret FX. Stat3 inhibitor stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma. PLoS One. 2013;8(1):e54565. PMID: 23382914. doi:10.1371/journal.pone.0054565.
   PubMed Web of Science ®Google Scholar
• Chang PY, Wu ZZ, Sun NK, Chao CC. EBV-encoded LMP-1 sensitizes nasopharyngeal carcinoma cells to genotoxic drugs by down-regulating cabin1 expression. J Cell Physiol. 2014;229(3):309–322. PMID: 23939952. doi:10.1002/jcp.24448.
   PubMed Web of Science ®Google Scholar
• Sakai A, Otani M, Miyamoto A, Yoshida H, Furuya E, Tanigawa N. Identification of phosphorylated serine-15 and −82 residues of HSPB1 in 5-fluorouracil-resistant colorectal cancer cells by proteomics. J Proteomics. 2012;75(3):806–818. PMID: 21989268. doi:10.1016/j.jprot.2011.09.023.
   PubMed Web of Science ®Google Scholar
• Yang YX, Sun XF, Cheng AL, Zhang GY, Yi H, Sun Y, Hu HD, Hu P, Ye F, Chen ZC, et al. Increased expression of HSP27 linked to vincristine resistance in human gastric cancer cell line. J Cancer Res Clin Oncol. 2009;135(2):181–189. PMID:18758817. doi:10.1007/s00432-008-0460-9.
   PubMed Web of Science ®Google Scholar
• Zhu F, Wang Y, Zeng S, Fu X, Wang L, Cao J. Involvement of annexin A1 in multidrug resistance of K562/ADR cells identified by the proteomic study. OMICS. 2009;13(6):467–476. PMID: 20001861. doi:10.1089/omi.2009.0046.
   PubMed Web of Science ®Google Scholar
• Onozawa H, Saito M, Saito K, Kanke Y, Watanabe Y, Hayase S, Sakamoto W, Ishigame T, Momma T, Ohki S, et al. Annexin A1 is involved in resistance to 5-FU in colon cancer cells. Oncol Rep. 2017;37(1):235–240. PMID:27840982. doi:10.3892/or.2016.5234.
   PubMed Web of Science ®Google Scholar
• Wang P, Zeng Y, Liu T, Zhang C, Yu PW, Hao YX, Luo HX, Liu G. Chloride intracellular channel 1 regulates colon cancer cell migration and invasion through ROS/ERK pathway. World J Gastroenterol. 2014;20(8):2071–2078. PMID: 24587680. doi:10.3748/wjg.v20.i8.2071.
   PubMed Web of Science ®Google Scholar
• Kang KA, Piao MJ, Kim KC, Kang HK, Chang WY, Park IC, Keum YS, Surh YJ, Hyun JW. Epigenetic modification of Nrf2 in 5-fluorouracil-resistant colon cancer cells: involvement of TET-dependent DNA demethylation. Cell Death Dis. 2014;5:e1183. PMID: 24743738. doi:10.1038/cddis.2014.149.
   PubMed Web of Science ®Google Scholar
• Kim JS, Chang JW, Yun HS, Yang KM, Hong EH, Kim DH, Um HD, Lee KH, Lee SJ, Hwang SG. Chloride intracellular channel 1 identified using proteomic analysis plays an important role in the radiosensitivity of HEp-2 cells via reactive oxygen species production. Proteomics. 2010;10(14):2589–2604. PMID: 20461716. doi:10.1002/pmic.200900523.
   PubMed Web of Science ®Google Scholar
• Cochaud S, Giustiniani J, Thomas C, Laprevotte E, Garbar C, Savoye AM, Cure H, Mascaux C, Alberici G, Bonnefoy N, et al.IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Sci Rep. 2013;3. PMID: 24316750. doi:10.1038/srep03456.
   PubMed Web of Science ®Google Scholar
• Sette G, Salvati V, Memeo L, Fecchi K, Colarossi C, Di MP, Signore M, Biffoni M, D’Andrea V, De Antoni E, et al. EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential. PLoS One. 2012;7(10):e46891. PMID: 23056514. doi:10.1371/journal.pone.0046891.
   PubMed Web of Science ®Google Scholar
• Lee JH, Sun D, Cho KJ, Kim MS, Hong MH, Kim IK, Lee JS, Lee JH. Overexpression of human 27 kDa heat shock protein in laryngeal cancer cells confers chemoresistance associated with cell growth delay. J Cancer Res Clin Oncol. 2007;133(1):37–46. PMID: 16906418. doi:10.1007/s00432-006-0143-3.
   PubMed Web of Science ®Google Scholar
• Qi W, White MC, Choi W, Guo C, Dinney C, McConkey DJ, Siefker-Radtke A. Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells. PLoS One. 2013;8(7):e69509. PMID: 23874968. doi:10.1371/journal.pone.0069509.
   PubMed Web of Science ®Google Scholar
• Ni PZ, He JZ, Wu ZY, Ji X, Chen LQ, Xu XE, Liao LD, Wu JY, Li EM, Xu LY. Overexpression of stathmin 1 correlates with poor prognosis and promotes cell migration and proliferation in oesophageal squamous cell carcinoma. Oncol Rep. 2017;38(6):3608–3618. PMID: 29039594. doi:10.3892/or.2017.6039.
   PubMed Web of Science ®Google Scholar
• Zhang J, Fu J, Pan Y, Zhang X, Shen L. Silencing of miR-1247 by DNA methylation promoted non-small-cell lung cancer cell invasion and migration by effects of STMN1. Onco Targets Ther. 2016;9:7297–7307. PMID: 27942223. doi:10.2147/OTT.S111291.
   PubMed Web of Science ®Google Scholar
• Bai T, Yokobori T, Altan B, Ide M, Mochiki E, Yanai M, Kimura A, Kogure N, Yanoma T, Suzuki M, et al. High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients. Br J Cancer. 2017;116(9):1177–1185. PMID: 28334732. doi:10.1038/bjc.2017.76.
   PubMed Web of Science ®Google Scholar
• Zhu HW, Jiang D, Xie ZY, Zhou MH, Sun DY, Zhao YG. Effects of stathmin 1 silencing by siRNA on sensitivity of esophageal cancer cells Eca-109 to paclitaxel. Genet Mol Res. 2015;14(4):18695–18702. PMID: 26782519. doi:10.4238/2015.December.28.18.
   PubMed Web of Science ®Google Scholar
• Yang H, Zhang Y, Zhao R, Wen YY, Fournier K, Wu HB, Yang HY, Diaz J, Laronga C, Lee MH. Negative cell cycle regulator 14-3-3sigma stabilizes p27 Kip1 by inhibiting the activity of PKB/Akt. Oncogene. 2006;25(33):4585–4594. PMID: 16532026. doi:10.1038/sj.onc.1209481.
   PubMed Web of Science ®Google Scholar
• Ide M, Nakajima T, Asao T, Kuwano H. Inactivation of 14-3-3sigma by hypermethylation is a rare event in colorectal cancers and its expression may correlate with cell cycle maintenance at the invasion front. Cancer Lett. 2004;207(2):241–249. PMID: 15072834. doi:10.1016/j.canlet.2003.11.009.
   PubMed Web of Science ®Google Scholar
• Vogel S, Herzinger T. The epithelium specific cell cycle regulator 14-3-3sigma is required for preventing entry into mitosis following ultraviolet B. Photodermatol Photoimmunol Photomed. 2013;29(6):300–310. PMID: 24102700. doi:10.1111/phpp.12071.
   PubMed Web of Science ®Google Scholar
• Qin X, Qiu F, Zou Z. TRIM25 is associated with cisplatin resistance in non-small-cell lung carcinoma A549 cell line via downregulation of 14-3-3σ. Biochem Biophys Res Commun. 2017;493:568–572. PMID:28867193. doi:10.1016/j.bbrc.2017.08.151.
   PubMed Web of Science ®Google Scholar
• Yang H, Zhao R, Lee MH. 14-3-3sigma, a p53 regulator, suppresses tumor growth of nasopharyngeal carcinoma. Mol Cancer Ther. 2006;5(2):253–260. MCT-05-0395.PMID: 16505098. doi:10.1158/1535-7163.
   PubMed Web of Science ®Google Scholar
• Yang HY, Wen YY, Chen CH, Lozano G, Lee MH. 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol. 2003;23(20):7096–7107. PMID:14517281. doi:10.1128/MCB.23.20.7096-7107.2003.
   PubMed Web of Science ®Google Scholar
• Chan SY, To KF, Leung SF, Yip WW, Mak MK, Chung GT, Lo KW. 14-3-3sigma expression as a prognostic marker in undifferentiated nasopharyngeal carcinoma. Oncol Rep. 2010;24(4):949–955. PMID: 20811675. doi:10.3892/or_00000941.
   PubMed Web of Science ®Google Scholar
• Holm R, Ali T, Svendsrud DH, Nesland JM, Kristensen GB, Lyng H. Expression of 14-3-3sigma in cervical squamous cell carcinomas: relationship with clinical outcome. Oncol Rep. 2009;22(1):11–15. PMID: 19513498. doi:10.3892/or_00000399.
   PubMed Web of Science ®Google Scholar
• Deng J, Gao G, Wang L, Wang T, Yu J, Zhao Z. Stratifin expression is a novel prognostic factor in human gliomas. Pathol Res Pract. 2011;207(11):674–679. PMID:21940111. doi:10.1016/j.prp.2011.08.005.
   PubMed Web of Science ®Google Scholar
• Raungrut P, Petjaroen P, Geater SL, Keeratichananont W, Phukaoloun M, Suwiwat S, Thongsuksai P. Methylation of 14-3-3σ gene and prognostic significance of 14-3-3σ expression in non-small cell lung cancer. Oncol Lett. 2017;14:5257–5264. PMID: 29113161. doi:10.3892/ol.2017.6881.
   PubMed Web of Science ®Google Scholar
• Zheng G, Xiong Y, Yi S, Zhang W, Peng B, Zhang Q, He Z. 14-3-3σ regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation. FEBS Lett. 2012;586:163–168. PMID:22192357. doi:10.1016/j.febslet.2011.11.034.
   PubMed Web of Science ®Google Scholar
• Qin L, Dong Z, Zhang JT. 14-3-3σ regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression. Oncotarget. 2016;7:17726–17736. PMID: 26894857. doi:10.18632/oncotarget.7394.
   PubMedGoogle Scholar
• Lai KK, Chan KT, Choi MY, Wang HK, Fung EY, Lam HY, Tan W, Tung LN, Tong DK, Sun RW, et al. 14-3-3σ confers cisplatin resistance in esophageal squamous cell carcinoma cells via regulating DNA repair molecules. Tumour Biol. 2016;37:2127–2136. PMID: 26346170. doi:10.1007/s13277-015-4018-6.
   PubMedGoogle Scholar
• Kim IK, Park SM, Cho HJ, Baek KE, Nam IK, Park SH, Ryu KJ, Ryu J, Choi J, Hong SC, et al. 14-3-3σ attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells. Oncotarget. 2013;4:2045–2056. PMID: 24185104. doi:10.18632/oncotarget.1334.
   PubMed Web of Science ®Google Scholar
• Cetintas VB, Tetik A, Cok G, Kucukaslan AS, Kosova B, Gunduz C, Veral A, Eroglu Z. Role of 14-3-3σ in resistance to cisplatin in non-small cell lung cancer cells. Cell Biol Int. 2013;37:78–86. PMID: 23339090. doi:10.1002/cbin.10006.
   PubMed Web of Science ®Google Scholar
• Li Z, Dong Z, Myer D, Yip-Schneider M, Liu J, Cui P, Schmidt CM, Zhang JT. Role of 14-3-3σ in poor prognosis and in radiation and drug resistance of human pancreatic cancers. BMC Cancer. 2010;10:598. PMID:21040574. doi:10.1186/1471-2407-10-598.
   PubMedGoogle Scholar
• Chen Z, Long L, Wang K, Cui F, Zhu L, Tao Y, Wu Q, Xiang M, Liang Y, Qiu S, et al. Identification of nasopharyngeal carcinoma metastasis-related biomarkers by iTRAQ combined with 2D-LC-MS/MS. Oncotarget. 2016;7(23):34022–34037. PMID: 27145374. doi:10.18632/oncotarget.9067.
   PubMedGoogle Scholar
• Sun G, Sui X, Han D, Gao J, Liu Y, Zhou L. TRIM59 promotes cell proliferation, migration and invasion in human hepatocellular carcinoma cells. Pharmazie. 2017;72(11):674–679. doi:10.1691/ph.2017.7659.PMID:29442042.
   PubMed Web of Science ®Google Scholar
• Song Y, Guo Q, Gao S, Hua K. Tripartite motif-containing protein 3 plays a role of tumor inhibitor in cervical cancer. Biochem Biophys Res Commun. 2018;498(3):686–692. PMID:29524410. doi:10.1016/j.bbrc.2018.03.046.
   PubMed Web of Science ®Google Scholar
• Hatakeyama S. .TRIM proteins and cancer. Nat Rev Cancer. 2011;11(11):792–804. PMID:21979307. doi:10.1038/nrc3139.
   PubMed Web of Science ®Google Scholar
• Napolitano LM, Meroni G. TRIM family: pleiotropy and diversification through homomultimer and heteromultimer formation. IUBMB Life. 2012;64(1):64–71. PMID: 22131136. doi:10.1002/iub.580.
   PubMed Web of Science ®Google Scholar
• Xing J, Weng L, Yuan B, Wang Z, Jia L, Jin R, Lu H, Li XC, Liu YJ, Zhang Z. Identification of a role for TRIM29 in the control of innate immunity in the respiratory tract. Nat Immunol. 2016;17(12):1373–1380. PMID:27695001. doi:10.1038/ni.3580.
   PubMed Web of Science ®Google Scholar
• Tan ST, Liu SY, Wu B. TRIM29 overexpression promotes proliferation and survival of bladder cancer cells through NF-κB signaling. Cancer Res Treat. 2016;48:1302–1312. PMID:26987391. doi:10.4143/crt.2015.381.
   PubMedGoogle Scholar
• Xing J, Zhang A, Zhang H, Wang J, Li XC, Zeng MS, Zhang Z. TRIM29 promotes DNA virus infections by inhibiting innate immune response. Nat Commun. 2017;8(1):945. PMID:29038422. doi:10.1038/s41467-017-00101-w.
   PubMed Web of Science ®Google Scholar
• Zeng SX, Cai QC, Guo CH, Zhi LQ, Dai X, Zhang DF, Ma W. High expression of TRIM29 (ATDC) contributes to poor prognosis and tumor metastasis by inducing epithelial‑mesenchymal transition in osteosarcoma. Oncol Rep. 2017;38:1645–1654. PMID:28731167. doi:10.3892/or.2017.5842.
   PubMed Web of Science ®Google Scholar
• Xu W, Xu B, Yao Y, Yu X, Cao H, Zhang J, Liu J, Sheng H. .RNA interference against TRIM29 inhibits migration and invasion of colorectal cancer cells. Oncol Rep. 2016;36(3):1411–1418. PMID:27430345. doi:10.3892/or.2016.4941.
   PubMed Web of Science ®Google Scholar
• Yuan Z, Villagra A, Peng L, Coppola D, Glozak M, Sotomayor EM, Chen J, Lane WS, Seto E, .The ATDC. (TRIM29) protein binds p53 and antagonizes p53-mediated functions. Mol Cell Biol. 2010;30(12):3004–3015. PMID:20368352. doi:10.1128/MCB.01023-09.
   PubMed Web of Science ®Google Scholar
• Qiu F, Xiong JP, Deng J, Xiang XJ. TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185. Int J Clin Exp Pathol. 2015;8(5):5053–5061. PMID:26191199.
   PubMed Web of Science ®Google Scholar
• Wan YM, Tian J, Qi L, Liu LM, Xu N. ANXA1 affects cell proliferation, invasion and epithelial-mesenchymal transition of oral squamous cell carcinoma. Exp Ther Med. 2017;14(5):5214–5218. PMID:29201239. doi:10.3892/etm.2017.5148.
   PubMed Web of Science ®Google Scholar
• Rohwer N, Bindel F, Grimm C, Lin SJ, Wappler J, Klinger B, Blüthgen N, Du Bois I, Schmeck B, Lehrach H, et al. Annexin A1 sustains tumor metabolism and cellular proliferation upon stable loss of HIF1A. Oncotarget. 2016;7(6):6693–6710. PMID: 26760764. doi:10.18632/oncotarget.6793.
   PubMedGoogle Scholar
• Han G, Lu K, Huang J, Ye J, Dai S, Ye Y, Zhang L. Effect of annexin A1 gene on the proliferation and invasion of esophageal squamous cell carcinoma cells and its regulatory mechanisms. Int J Mol Med. 2017;39(2):357–363. PMID: 28035369. doi:10.3892/ijmm.2016.2840.
   PubMed Web of Science ®Google Scholar
• Okano M, Kumamoto K, Saito M, Onozawa H, Saito K, Abe N, Ohtake T, Takenoshita S. Upregulated Annexin A1 promotes cellular invasion in triple-negative breast cancer. Oncol Rep. 2015;33(3):1064–1070. PMID:25592491. doi:10.3892/or.2015.3720.
   PubMed Web of Science ®Google Scholar
• Yu S, Meng Q, Hu H, Zhang M. Correlation of ANXA1 expression with drug resistance and relapse in bladder cancer. Int J Clin Exp Pathol. 2014;7(9):5538–5548. PMID:25337195. doi: 1936-2625/ IJCEP0001534.
   PubMed Web of Science ®Google Scholar
• De Marchi T, Timmermans AM, Smid M, Look MP, Stingl C, Opdam M, Linn SC, Sweep FC, Span PN, Kliffen M, et al. Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer. Oncotarget. 2016;7(3):3098–3110. PMID:26657294. doi:10.18632/oncotarget.6521.
   PubMedGoogle Scholar
• Croxtall JD, Choudhury Q, Flower RJ. Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol. 2000;130(2):289–298. PMID:10807665. doi:10.1038/sj.bjp.0703272.
   PubMed Web of Science ®Google Scholar
• Sawyer ST, Cohen S. Epidermal growth factor stimulates the phosphorylation of the calcium-dependent 35,000-dalton substrate in intact A-431 cells. J Biol Chem. 1985;260(14):8233–8236. PMID:2409081
   PubMed Web of Science ®Google Scholar
• Yuan Y, Anbalagan D, Lee LH, Samy RP, Shanmugam MK, Kumar AP, Sethi G, Lobie PE, Lim LH. ANXA1 inhibits miRNA-196a in a negative feedback loop through NF-kB and c-Myc to reduce breast cancer proliferation. Oncotarget. 2016;7(19):27007–27020. PMID:27105503. doi:10.18632/oncotarget8875.
   PubMedGoogle Scholar
• Liu QH, Shi ML, Bai J, Zheng JN. Identification of ANXA1 as a lymphatic metastasis and poor prognostic factor in pancreatic ductal adenocarcinoma. Asian Pac J Cancer Prev. 2015;16(7):2719–2724. PMID:25854353. doi:10.7314/APJCP.2015.16.7.2719.
   PubMedGoogle Scholar
• Zhang X, Li X, Li X, Zheng L, Lei L. ANXA1 silencing increases the sensitivity of cancer cells to low-concentration arsenic trioxide treatment by inhibiting ERK MAPK activation. Tumori. 2015;101(4):360–367. PMID:25983101. doi:10.5301/tj.5000315.
   PubMed Web of Science ®Google Scholar
• Unwin RD, Griffiths JR, Whetton AD. Simultaneous analysis of relative protein expression levels across multiple samples using iTRAQ isobaric tags with 2D nano LC-MS/MS. Nat Protoc. 2010;5(9):1574–1582. PMID: 21085123. doi:10.1038/nprot.2010.123.
   PubMed Web of Science ®Google Scholar
• Wang L, Sun L, Huang J, Jiang M. Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation. Cell Prolif. 2011;44(3):291–299. PMID:21535270. doi:10.1111/j.1365-2184.2011.00752.x.
   PubMed Web of Science ®Google Scholar
• Wang L, Huang J, Jiang M, Sun L. Survivin (BIRC5) cell cycle computational network in human no-tumor hepatitis/cirrhosis and hepatocellular carcinoma transformation. J Cell Biochem. 2011;112(5):1286–1294. PMID:21312234. doi:10.1002/jcb.23030.
   PubMed Web of Science ®Google Scholar